medigraphic.com
ISSN 1561-3062 (Electronic)

2014, Number 3

<< Back Next >>

Revista Cubana de Obstetricia y Ginecología 2014; 40 (3)

Mifepristone efficacy for emergency contraception when comparing 5 and 10 milligrams doses

García MR, González SA, García ML, Llibre GJJ, Delgado GMJ, Peñalver CAM

Language: Spanish
References: 27
Page: 326-335
PDF size: 90.20 Kb.


ABSTRACT

Introduction: unwanted pregnancies and unsafe abortions for women are now a serious health problem worldwide. Emergency contraception can help overcoming this negative situation, and therefore to reduce maternal mortality due to this cause.
Objectives: to compare mifepristone efficacy and safety as emergency contraception in a 5 mg dose versus a 10 mg dose.
Methods: a prospective, longitudinal observational study was conducted at Eusebio Hernández Teaching Hospital in Havana from 1st January, 2011 to 1st September, 2012. A sample of 300 women was randomly selected into two groups. One group received a 5 mg dose of mifepristone and the other a 10 mg dose of mifepristone. Both doses were administered for 6 days (144 hours) as emergency contraception. The study was performed double blind.
Results: there was a predominance of women of 28 years on average, 75 % reported not using contraception as a reason for requesting emergency contraception and 99 % reported previous use of a contraceptive method. 1.2 % of pregnancies were reported in both, the group receiving 5 mg of mifepristone and in 10 mg mifepristone.
Conclusions: same contraceptives results are achieved when using 5 mg dose of mifepristone as when using 10 mg of this medicine.


REFERENCES

  1. Creinin MD, Fox MC, Teal S. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol.2007;103:851-9.

  2. Hamoda H, Ashok PW, Stalder C, Flett GMM. A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception. Obstet Gynecol. 2006;104:1307-13.

  3. Ashok PW, Wagaarachi PT, Flett GM, Templeton A. Mifepristone as a late post-coital contraceptive. Hum Reprod. 2009;16:72-5.

  4. Ho PC, Kwan MSW. “A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception” Hum Reprod. 1995;8(3):389-92.

  5. Gemzell-Danielsson K, Marions L. Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception. Hum Reprod. 2006;10:341-8.

  6. World Health Organization. Task Force on Postovulatory Methods of Fertility Regulation. Randomized controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998;352:428-33.

  7. Von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bartfai G, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomized trial. Lancet 2002;360:1803-10.

  8. Trussell J, Ellertson C, von Hertzen H, Bigrigg A, Webb A, Evans M, et al. Estimating the effectiveness of emergency contraception pills. Contraception 2003;67:259-65.

  9. Consensus Statement on Emergency Contraception”, Conference on Emergency Contraception in Bellagio, Italy, April 1995.

  10. Mahmood T, Saridogan E, Smutna S, Habib AM, Djahanbakhch O. The effect of ovarian steroids on epithelial ciliary beat frequency in the human Fallopian tube. Hum Reprod. 1998;13:2991-4.

  11. Piaggio G, Heng Z, von Hertzen H, Xiao BL, Cheng L. Combined estimates of effectiveness of mifepristone 10 mg in emergency contraception. Contraception. 2006;68:439-46.

  12. Von Hertzen H, Piaggio G, Ding J. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet. 2008;360(9348):1803-10.

  13. Xiao BL, Zhao H, Piaggio G, Von Hertzen H. Expanded clinical trial of emergency contraception with 10 mg mifepristone. Contraception. 2006;68:431-7.

  14. World Health Organization. Task force on post-ovulatory methods of fertility regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomized trial. Lancet 1999;353:697-02.

  15. Gemzell Danielsson K, Westlund P, Swahn ML, Bygdeman M, Seppala M. Effect of low weekly doses of mifepristone on ovarian function and endometrial development. Hum Reprod 1996;11:256-4.

  16. Gemzell-Danielsson K, Mandl I, Marions L. Mechanisms of action of mifepristone when used for emergency contraception. Contraception. 2006;67:471-6.

  17. Ghosh D, Lalitkumar PGL, Wong VJ, Hendrickx AG, Sengupta J. Preimplantation embryo morphology following early luteal phase anti-nidatory treatment with mifepristone (RU486) in the rhesus monkey. Hum Reprod. 2000;5:180-8.

  18. Trussell J, Rodríguez G, Ellerston C. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception. 1998;57:363-9.

  19. Laporte JR, Tognoni G. Principios de epidemiología del medicamento. Ediciones Cient-Tecn, S.A. 1993;2:6-1.

  20. Vasilaskis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception. 1999;59:79.

  21. Ellertson C, Evans M, Ferden S, Leadbetter C, Spears A, Johnstone K, et al. Extending the time limit for starting the Yuzpe regimen of emergency contraception to 120 hours. Obstet Gynecol. 2003;101:1168-71.

  22. Piaggio G, von Hertzen H, Grimes DA, Van Look PF. On behalf of the Task Force on Postovulatory Methods of Fertility Regulation. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Lancet. 1999;353:721.

  23. Rodriguez I, Grou F, Jly J. Effectiveness of emergency contraceptive pills between 72 and 120 hours after unprotected intercourse. Am J Obstet Gynecol. 2001;184:531-7.

  24. Carbonell JL, García Mirás R. Emergency Contraception in Cuba with 10 mg of Mifepristone. The European Journal of Contraception & Reproductive Health Care. 2007;12(2):162-7.

  25. World Health Organization. Emergency Contraception: a guide for service delivery. Geneva: OMS; 1998.

  26. International Planned Parenthood Federation. Med Bull. 2004;38(1):1-2.

  27. 27.World Health Organization, Reproductive Health and Research. Improving access to quality care in family planning: medical eligibility criteria for contraceptive use. 3rd edition. Geneva:OMS; 2003. Disponible en: http://www.who.int/reproductive-health




2020     |     www.medigraphic.com